AU3229097A - Novel anandamide amidase inhibitors as analgesic agents - Google Patents

Novel anandamide amidase inhibitors as analgesic agents

Info

Publication number
AU3229097A
AU3229097A AU32290/97A AU3229097A AU3229097A AU 3229097 A AU3229097 A AU 3229097A AU 32290/97 A AU32290/97 A AU 32290/97A AU 3229097 A AU3229097 A AU 3229097A AU 3229097 A AU3229097 A AU 3229097A
Authority
AU
Australia
Prior art keywords
novel
analgesic agents
anandamide amidase
amidase inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32290/97A
Other languages
English (en)
Inventor
William Adam Hill
Sonyan Lin
Alexandros Makriyannis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONNECTICUT THE, University of
Original Assignee
CONNECTICUT THE, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CONNECTICUT THE, University of filed Critical CONNECTICUT THE, University of
Publication of AU3229097A publication Critical patent/AU3229097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
AU32290/97A 1996-05-31 1997-05-30 Novel anandamide amidase inhibitors as analgesic agents Abandoned AU3229097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/658,949 US5688825A (en) 1996-05-31 1996-05-31 Anandamide amidase inhibitors as analgesic agents
US08658949 1996-05-31
PCT/US1997/009613 WO1997045407A1 (en) 1996-05-31 1997-05-30 Novel anandamide amidase inhibitors as analgesic agents

Publications (1)

Publication Number Publication Date
AU3229097A true AU3229097A (en) 1998-01-05

Family

ID=24643395

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32290/97A Abandoned AU3229097A (en) 1996-05-31 1997-05-30 Novel anandamide amidase inhibitors as analgesic agents

Country Status (8)

Country Link
US (4) US5688825A (en:Method)
EP (2) EP1021406B1 (en:Method)
JP (1) JP2000511540A (en:Method)
AU (1) AU3229097A (en:Method)
CA (1) CA2255620C (en:Method)
DE (1) DE69737039T2 (en:Method)
ES (1) ES2278391T3 (en:Method)
WO (1) WO1997045407A1 (en:Method)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688825A (en) * 1996-05-31 1997-11-18 University Of Connecticut Anandamide amidase inhibitors as analgesic agents
ATE277921T1 (de) * 1998-05-04 2004-10-15 Univ Connecticut Selektiv auf den cb2-rezeptor wirkende cannabinoide
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
CA2337822A1 (en) * 1998-06-09 1999-12-16 The University Of Connecticut Inhibitors of the anandamide transporter as analgesic agents
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) * 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
DE60042004D1 (de) 1999-04-28 2009-05-28 Toray Industries Stoffe zur enternung von cannabinoiden und säulen mit diesen stoffen zur entfernung von cannabinoiden
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
JP2003511469A (ja) 1999-10-18 2003-03-25 ユニバーシティ オブ コネチカット 抹消カンナビノイド受容体（ｃｂ２）選択的配位子
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
CA2387846A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
WO2002012167A1 (es) * 2000-07-28 2002-02-14 Universidad Complutense De Madrid Derivados de acido araquidonico con afinidad por el transportador de anandamida
ES2174716B1 (es) * 2000-07-28 2004-08-01 Universidad Complutense De Madrid Nuevos derivados de acido araquidonico con afinidad por el transportador de anandamida.
ES2181601B2 (es) * 2001-07-27 2004-04-01 Univ Madrid Complutense Derivados de acido araquidonico con afinidad por el transportador de anandamida
US7329651B2 (en) * 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
ATE478670T1 (de) 2001-01-29 2010-09-15 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
EP1385520A4 (en) * 2001-02-08 2007-03-21 Nps Pharma Inc METHODS AND COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRICAL DISEASES AND FOR THE IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT THEREOF
CA2452881C (en) * 2001-07-13 2012-03-06 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
CA2464333C (en) * 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US8034843B2 (en) * 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
US20040063726A1 (en) * 2002-02-08 2004-04-01 Artman Linda D Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
AU2003228654A1 (en) * 2002-04-29 2003-11-17 The General Hospital Corporation Compositions and methods for preventing abuse of orally administered medications
MXPA04011390A (es) * 2002-05-16 2005-02-17 Sepracor Inc Aminas que inhiben un transportador de anandamida de mamifero, y metodos de uso de las mismas.
EP1509250B1 (en) 2002-06-06 2008-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
CN101287411B (zh) 2005-04-28 2013-03-06 普罗秋斯生物医学公司 药物信息系统及其用途
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
CA2702950A1 (en) * 2007-10-16 2009-04-23 Northeastern University Methods and compounds for modulating cannabinoid activity
US20110305751A1 (en) 2009-02-20 2011-12-15 To-Bbb Holding B.V. Glutathione-based drug delivery system
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
ES2873962T3 (es) * 2014-06-06 2021-11-04 Scripps Research Inst Compuestos de fluoruro de azufre (VI) y métodos para la preparación de los mismos
CN112121852B (zh) * 2020-08-27 2021-09-24 中山大学 催化剂组合物及催化剂组合物或催化剂用于催化亲核取代反应的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3465024A (en) * 1966-11-14 1969-09-02 Allied Chem Process for the preparation of isocyanates
US3577458A (en) * 1966-11-14 1971-05-04 Allied Chem Process for the preparation of isocyanates
US5804601A (en) * 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5688825A (en) * 1996-05-31 1997-11-18 University Of Connecticut Anandamide amidase inhibitors as analgesic agents

Also Published As

Publication number Publication date
EP1021406B1 (en) 2006-11-29
ES2278391T3 (es) 2007-08-01
US6579900B2 (en) 2003-06-17
JP2000511540A (ja) 2000-09-05
DE69737039T2 (de) 2007-06-21
EP1021406A1 (en) 2000-07-26
CA2255620A1 (en) 1997-12-04
WO1997045407A1 (en) 1997-12-04
EP1775286A1 (en) 2007-04-18
US5688825A (en) 1997-11-18
CA2255620C (en) 2008-01-29
US20020091153A1 (en) 2002-07-11
US6391909B1 (en) 2002-05-21
DE69737039D1 (de) 2007-01-11
US5874459A (en) 1999-02-23

Similar Documents

Publication Publication Date Title
AU3229097A (en) Novel anandamide amidase inhibitors as analgesic agents
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU3140695A (en) 1h-indole-1-functional spla2 inhibitors
AU3102397A (en) Metalloprotease inhibitors
AU4423499A (en) Novel analgesic agents
AU6477498A (en) Scale inhibitors
AU4875196A (en) Novel thrombin inhibitors
AU3832895A (en) Thrombin inhibitors
AU4791797A (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
AU3985897A (en) 1,3-diheterocyclic metalloprotease inhibitors
AU4787596A (en) Thrombin inhibitors
AU7497596A (en) Thrombin inhibitors
AU4153297A (en) Spirocyclic metalloprotease inhibitors
AU3941797A (en) Novel thrombin inhibitors
AU3198095A (en) Indene spla2 inhibitors
AU4863696A (en) Bridged indoles as matrix metalloprotease inhibitors
AU9059798A (en) Urokinase inhibitors
AU7139598A (en) Protease inhibitors
AU692123B2 (en) 5alpha-reductase inhibitors
AU5589298A (en) Phenyl acetamides as spla2 inhibitors
AU6627996A (en) Prolyl endopeptidase inhibitors
AU4128597A (en) Phosphatidylcholine synthesis inhibitors
AU1393900A (en) Morpholino-ethoxybenzofuran protease inhibitors
AU1149797A (en) Naphthyl glyoxamides as spla2 inhibitors
AU2373600A (en) Novel spla2 inhibitors